---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-080474"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-07-22T21:25:23+00:00"
generated_at: "2026-07-22T21:26:05.991417+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics completes enrollment of 750 patients in SYMON-II sepsis study ahead of schedule

## Summary
- Enrolled 750 patients ahead of plan in pivotal SYMON-II study evaluating Symphony IL-6 for early sepsis mortality risk assessment.
- Preliminary observations indicate an approximately 17% 28-day mortality rate, providing a robust clinical dataset.
- Study enrolled patients across leading U.S. healthcare institutions; results to support planned 510(k) submission to FDA.
- Company expects to complete data cleaning, statistical analysis, and clinical reporting over the coming months.

## SEC filing metadata
- accession: 0001213900-26-080474
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-07-22T21:25:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026080474/0001213900-26-080474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026080474/ea0298955-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-080474
- JSON: https://secwatch.observer/filing/0001213900-26-080474.json
- Plain text: https://secwatch.observer/filing/0001213900-26-080474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.